Literature DB >> 15816891

Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation.

Nzisa Mutinga1, Daniel C Brennan, Mark A Schnitzler.   

Abstract

HLA matching contributes to the disparity in Caucasian compared to minority kidney transplantation. HLA-B locus matching was eliminated from kidney allocation to shift a projected 166 organs from Caucasians to minorities annually. This study estimated the economic and quality-of-life impact of this policy. Cost-effectiveness analysis was performed using a Markov model. Data from the United States Renal Data System (USRDS) were used to estimate race-specific outcomes, patient and graft survival, quality-adjusted life years (QALYs) and medical costs in U.S. dollars. The greatest benefit is expected in African Americans, with expected savings of US 7.5 million dollars and 243 QALYs. Smaller cost and QALY benefits are seen in other minority groups. In Caucasians, a loss of 7.0 million dollars and a decrease of 967 QALYs are expected with the shift of organs. Overall, this policy is expected to save US 5400 dollars for each QALY that is lost. The same increase in minority transplantation would be expected from increasing Caucasian donation rates by 5.5%, or African-American donation by 29.0%, each producing large cost savings and QALY gains. Policies to increase minority transplants by increasing donation rates may prove more cost effective than the elimination of HLA-B matching from deceased donor kidney allocation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816891     DOI: 10.1111/j.1600-6143.2005.00802.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy.

Authors:  Joseph Menzin; Lisa M Lines; Daniel E Weiner; Peter J Neumann; Christine Nichols; Lauren Rodriguez; Irene Agodoa; Tracy Mayne
Journal:  Pharmacoeconomics       Date:  2011-10       Impact factor: 4.981

2.  A Systematic Review of Kidney Transplantation Decision Modelling Studies.

Authors:  Mohsen Yaghoubi; Sonya Cressman; Louisa Edwards; Steven Shechter; Mary M Doyle-Waters; Paul Keown; Ruth Sapir-Pichhadze; Stirling Bryan
Journal:  Appl Health Econ Health Policy       Date:  2022-08-09       Impact factor: 3.686

3.  Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.

Authors:  Stephanie R Earnshaw; Christopher N Graham; William D Irish; Reiko Sato; Mark A Schnitzler
Journal:  J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 10.121

4.  Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.

Authors:  Gerardo Machnicki; Jean-Francois Ricci; Daniel C Brennan; Mark A Schnitzler
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Non-medical factors influencing access to renal transplantation.

Authors:  Eszter Panna Vamos; Marta Novak; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-04-07       Impact factor: 2.370

6.  Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L.

Authors:  Bernadette Li; John A Cairns; Heather Draper; Christopher Dudley; John L Forsythe; Rachel J Johnson; Wendy Metcalfe; Gabriel C Oniscu; Rommel Ravanan; Matthew L Robb; Paul Roderick; Charles R Tomson; Christopher J E Watson; J Andrew Bradley
Journal:  Value Health       Date:  2017-05-12       Impact factor: 5.725

Review 7.  Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review.

Authors:  Sameera Senanayake; Nicholas Graves; Helen Healy; Keshwar Baboolal; Sanjeewa Kularatna
Journal:  Cost Eff Resour Alloc       Date:  2020-05-19

Review 8.  Cost-effectiveness of Deceased-donor Renal Transplant Versus Dialysis to Treat End-stage Renal Disease: A Systematic Review.

Authors:  Rui Fu; Nigar Sekercioglu; Whitney Berta; Peter C Coyte
Journal:  Transplant Direct       Date:  2020-01-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.